Plandai Biotechnology Inc (OTCMKTS:PLPL) and USN revised their three-year agreement, under which the nutrition and wellness company will use Phytofare® as the exclusive green-tea complex in all of their products in South Africa and the EU exchange for assured pricing and concessions from Plandaí. The company together with its subsidiary firms advanced superior quality phyto-available extracts.
It looks after every aspect of the development right from cultivation of raw materials to producing the component extracts in-house. This enables the company to assure supply continuity and quality control throughout the manufacturing and development process. Plandai customers are from varied industries including beverages, cosmeceutical, wellness, anti-aging, and pharmaceutical. USN comes in the list of reputed and comprehensive entities offering premium quality health and nutrition supplements and driving the sports nutrition industry from front globally.
In last trading session, the stock price of Plandai dropped more than 3% to close the week at $0.126.
Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Submits Form 10-Q
Earlier in August, Ritter Pharmaceuticals Inc (NASDAQ:RTTR) submitted Form 10-Q wherein the company revealed that it has not recorded any revenue since its inception. The ability to record revenue in coming period will depend on the development and regulatory approval for RP-G28 in the U.S. Further, the company intends to opt for a partnering deal to commercialize RP-G28 outside the United States.
Ritter expects to commence additional clinical trials and research and development activities in the future. It has used all its resources to advance the R&D plans including clinical as well as non-clinical trials, manufacturing advancement measures and many others. From inception through end of June 2015, Ritter has recorded nearly $4.2 million as R&D expenses.
Metabolix, Inc. (NASDAQ:MBLX) Introduces Yield10 Bioscience
Biodegradable plastics developer firm Metabolix, Inc. (NASDAQ:MBLX) introduced Yield10 Bioscience team so as to support development and commercialization activities in crop science using “T3 transcriptome-targeted” metabolic engineering platform to enhance crop yields.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: